Literature DB >> 27815040

The addition of ketone bodies alleviates mitochondrial dysfunction by restoring complex I assembly in a MELAS cellular model.

Samuel Frey1, Guillaume Geffroy1, Valerie Desquiret-Dumas2, Naig Gueguen2, Celine Bris2, Sophie Belal1, Patrizia Amati-Bonneau2, Arnaud Chevrollier1, Magalie Barth3, Daniel Henrion1, Guy Lenaers1, Dominique Bonneau2, Pascal Reynier2, Vincent Procaccio4.   

Abstract

Ketogenic Diet used to treat refractory epilepsy for almost a century may represent a treatment option for mitochondrial disorders for which effective treatments are still lacking. Mitochondrial complex I deficiencies are involved in a broad spectrum of inherited diseases including Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes syndrome leading to recurrent cerebral insults resembling strokes and associated with a severe complex I deficiency caused by mitochondrial DNA (mtDNA) mutations. The analysis of MELAS neuronal cybrid cells carrying the almost homoplasmic m.3243A>G mutation revealed a metabolic switch towards glycolysis with the production of lactic acid, severe defects in respiratory chain activity and complex I disassembly with an accumulation of assembly intermediates. Metabolites, NADH/NAD+ ratio, mitochondrial enzyme activities, oxygen consumption and BN-PAGE analysis were evaluated in mutant compared to control cells. A severe complex I enzymatic deficiency was identified associated with a major complex I disassembly with an accumulation of assembly intermediates of 400kDa. We showed that Ketone Bodies (KB) exposure for 4weeks associated with glucose deprivation significantly restored complex I stability and activity, increased ATP synthesis and reduced the NADH/NAD+ ratio, a key component of mitochondrial metabolism. In addition, without changing the mutant load, mtDNA copy number was significantly increased with KB, indicating that the absolute amount of wild type mtDNA copy number was higher in treated mutant cells. Therefore KB may constitute an alternative and promising therapy for MELAS syndrome, and could be beneficial for other mitochondrial diseases caused by complex I deficiency.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Complex I assembly; Ketone bodies; MELAS syndrome; Mitochondria; Mitochondrial DNA; Mitochondrial diseases

Mesh:

Substances:

Year:  2016        PMID: 27815040     DOI: 10.1016/j.bbadis.2016.10.028

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  13 in total

Review 1.  Therapeutic Approaches to Treat Mitochondrial Diseases: "One-Size-Fits-All" and "Precision Medicine" Strategies.

Authors:  Emanuela Bottani; Costanza Lamperti; Alessandro Prigione; Valeria Tiranti; Nicola Persico; Dario Brunetti
Journal:  Pharmaceutics       Date:  2020-11-11       Impact factor: 6.321

Review 2.  Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics.

Authors:  Patrycja Puchalska; Peter A Crawford
Journal:  Cell Metab       Date:  2017-02-07       Impact factor: 27.287

Review 3.  Current and Emerging Clinical Treatment in Mitochondrial Disease.

Authors:  Rory J Tinker; Albert Z Lim; Renae J Stefanetti; Robert McFarland
Journal:  Mol Diagn Ther       Date:  2021-03-01       Impact factor: 4.074

4.  Ketogenic diet attenuates hepatopathy in mouse model of respiratory chain complex III deficiency caused by a Bcs1l mutation.

Authors:  Janne Purhonen; Jayasimman Rajendran; Matthias Mörgelin; Kristiina Uusi-Rauva; Shintaro Katayama; Kaarel Krjutskov; Elisabet Einarsdottir; Vidya Velagapudi; Juha Kere; Matti Jauhiainen; Vineta Fellman; Jukka Kallijärvi
Journal:  Sci Rep       Date:  2017-04-19       Impact factor: 4.379

5.  Anti-replicative recombinant 5S rRNA molecules can modulate the mtDNA heteroplasmy in a glucose-dependent manner.

Authors:  Romuald Loutre; Anne-Marie Heckel; Damien Jeandard; Ivan Tarassov; Nina Entelis
Journal:  PLoS One       Date:  2018-06-18       Impact factor: 3.240

6.  Selection and Characterization of Palmitic Acid Responsive Patients with an OXPHOS Complex I Defect.

Authors:  Tom E J Theunissen; Mike Gerards; Debby M E I Hellebrekers; Florence H van Tienen; Rick Kamps; Suzanne C E H Sallevelt; Elvira N M M-D Hartog; Hans R Scholte; Robert M Verdijk; Kees Schoonderwoerd; Irenaeus F M de Coo; Radek Szklarczyk; Hubert J M Smeets
Journal:  Front Mol Neurosci       Date:  2017-10-18       Impact factor: 5.639

7.  Induced Ketosis as a Treatment for Neuroprogressive Disorders: Food for Thought?

Authors:  Gerwyn Morris; Basant K Puri; Andre Carvalho; Michael Maes; Michael Berk; Anu Ruusunen; Lisa Olive
Journal:  Int J Neuropsychopharmacol       Date:  2020-06-24       Impact factor: 5.176

8.  Ketogenic treatment reduces the percentage of a LHON heteroplasmic mutation and increases mtDNA amount of a LHON homoplasmic mutation.

Authors:  Sonia Emperador; Ester López-Gallardo; Carmen Hernández-Ainsa; Mouna Habbane; Julio Montoya; M Pilar Bayona-Bafaluy; Eduardo Ruiz-Pesini
Journal:  Orphanet J Rare Dis       Date:  2019-06-21       Impact factor: 4.123

Review 9.  More Than One HMG-CoA Lyase: The Classical Mitochondrial Enzyme Plus the Peroxisomal and the Cytosolic Ones.

Authors:  María Arnedo; Ana Latorre-Pellicer; Cristina Lucia-Campos; Marta Gil-Salvador; Rebeca Antoñanzas-Peréz; Paulino Gómez-Puertas; Gloria Bueno-Lozano; Beatriz Puisac; Juan Pié
Journal:  Int J Mol Sci       Date:  2019-12-04       Impact factor: 5.923

Review 10.  Nutritional Ketosis and Mitohormesis: Potential Implications for Mitochondrial Function and Human Health.

Authors:  Vincent J Miller; Frederick A Villamena; Jeff S Volek
Journal:  J Nutr Metab       Date:  2018-02-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.